Illumina Inc
NASDAQ:ILMN
Intrinsic Value
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. [ Read More ]
The intrinsic value of one ILMN stock under the Base Case scenario is 117.19 USD. Compared to the current market price of 117.65 USD, Illumina Inc is Fairly Valued.
Valuation Backtest
Illumina Inc
Run backtest to discover the historical profit from buying and selling ILMN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Illumina Inc
Current Assets | 2.6B |
Cash & Short-Term Investments | 1.1B |
Receivables | 752m |
Other Current Assets | 803m |
Non-Current Assets | 7.5B |
Long-Term Investments | 196m |
PP&E | 1.6B |
Intangibles | 5.5B |
Other Non-Current Assets | 217m |
Current Liabilities | 1.6B |
Accounts Payable | 245m |
Accrued Liabilities | 994m |
Other Current Liabilities | 331m |
Non-Current Liabilities | 2.8B |
Long-Term Debt | 1.5B |
Other Non-Current Liabilities | 1.3B |
Earnings Waterfall
Illumina Inc
Revenue
|
4.5B
USD
|
Cost of Revenue
|
-1.8B
USD
|
Gross Profit
|
2.7B
USD
|
Operating Expenses
|
-2.8B
USD
|
Operating Income
|
-76m
USD
|
Other Expenses
|
-1.1B
USD
|
Net Income
|
-1.2B
USD
|
Free Cash Flow Analysis
Illumina Inc
What is Free Cash Flow?
ILMN Profitability Score
Profitability Due Diligence
Illumina Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Illumina Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
ILMN Solvency Score
Solvency Due Diligence
Illumina Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Illumina Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ILMN Price Targets Summary
Illumina Inc
According to Wall Street analysts, the average 1-year price target for ILMN is 157.71 USD with a low forecast of 101 USD and a high forecast of 265.65 USD.
Ownership
ILMN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ILMN Price
Illumina Inc
Average Annual Return | -7.19% |
Standard Deviation of Annual Returns | 27.09% |
Max Drawdown | -82% |
Market Capitalization | 18.7B USD |
Shares Outstanding | 158 900 000 |
Percentage of Shares Shorted | 3.75% |
ILMN News
Last Important Events
Illumina Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Illumina Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 9,800 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The firm's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one ILMN stock under the Base Case scenario is 117.19 USD.
Compared to the current market price of 117.65 USD, Illumina Inc is Fairly Valued.